Clinical effectiveness and safety of fingolimod in relapsing remitting multiple sclerosis in Western Iran

References

1. ↵
   1. Hunter SF,
   2. Bowen JD,
   3. Reder AT

   (2016) The Direct Effects of Fingolimod in the Central Nervous System: Implications for Relapsing Multiple Sclerosis. CNS Drugs 30, 135–147.
2. ↵
   1. Slowik A,
   2. Schmidt T,
   3. Beyer C,
   4. Amor S,
   5. Clarner T,
   6. Kipp M

   (2015) The sphingosine 1-phosphate receptor agonist FTY720 is neuroprotective after cuprizone-induced CNS demyelination. Br J Pharmacol 172, 80–92.
3. ↵
   1. Gajofatto A,
   2. Turatti M,
   3. Monaco S,
   4. Benedetti MD

   (2015) Clinical efficacy, safety, and tolerability of fingolimod for the treatment of relapsing-remitting multiple sclerosis. Drug Healthc Patient Saf 7, 157–167.
4. ↵
   1. Kappos L,
   2. O'Connor P,
   3. Radue EW,
   4. Polman C,
   5. Hohlfeld R,
   6. Selmaj K,
   7. et al.

   (2015) Long-term effects of fingolimod in multiple sclerosis: The randomized FREEDOMS extension trial. Neurology 84, 1582–1591.
5. ↵
   1. Yoshii F,
   2. Moriya Y,
   3. Ohnuki T,
   4. Ryo M,
   5. Takahashi W

   (2017) Neurological safety of fingolimod: An updated review. Clin Exp Neuroimmunol 8, 233–243.
6. ↵
   1. Piehl F

   (2014) A changing treatment landscape for multiple sclerosis: challenges and opportunities. J Intern Med 275, 364–381.
7. ↵
   1. La Mantia L,
   2. Tramacere I,
   3. Firwana B,
   4. Pacchetti I,
   5. Palumbo R,
   6. Filippini G

   (2016) Fingolimod for relapsing-remitting multiple sclerosis. Cochrane Database Syst Rev 4, CD009371.
8. ↵
   1. Khatri B

   (2016) Fingolimod in the treatment of relapsing–remitting multiple sclerosis: long-term experience and an update on the clinical evidence. Ther Adv Neurol Disord 9, 130–147.
9. ↵
   1. D'Amico E,
   2. Zanghı A,
   3. Leone C,
   4. Tumani H,
   5. Patti F

   (2016) Treatment-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: A Comprehensive Review of Current Evidence and Future Needs. Drug Saf 39, 1163–1174.
10. ↵
    1. Pfender N,
    2. Jelcic I,
    3. Linnebank M,
    4. Schwarz U,
    5. Martin R

    (2015) Reactivation of herpes virus under fingolimod: a case of severe herpes simplex encephalitis. Neurology 84, 2377–2378.
11. ↵
    1. Issa NP,
    2. Hentati A

    (2015) VZV encephalitis that developed in an immunized patient during fingolimod therapy. Neurology 84, 99–100.
12. ↵
    1. Hellmann MA,
    2. Lev N,
    3. Lotan I,
    4. Mosberg-Galili R,
    5. Inbar E,
    6. Luckman J,
    7. et al.

    (2014) Tumefactive demyelination and a malignant course in an MS patient during and following fingolimod therapy. J Neurol Sci 344, 193–197.
13. ↵
    1. Correale J,
    2. Flores J,
    3. Bonitto JG,
    4. Rodríguez CC,
    5. Oliveira EML

    (2015) Use of Fingolimod in the Management of Relapsing–Remitting Multiple Sclerosis: Experience from Latin America. Adv Ther 32, 612–625.
14. ↵
    1. Vischer N,
    2. Pfeiffer C,
    3. Joller A,
    4. Klingmann I,
    5. Ka A,
    6. Kpormegbe SK,
    7. et al.

    (2016) The Good Clinical Practice guideline and its interpretation - perceptions of clinical trial teams in sub-Saharan Africa. Trop Med Int Health 21, 1040–1048.
15. ↵
    1. World Medical Association Declaration of Helsinki Ethical Principles for Medical Research Involving Human Subjects

    (2013) JAMA 310, 2191–2194.
16. ↵
    1. Runia TF,
    2. Jafari N,
    3. Hintzen RQ

    (2013) Application of the 2010 revised criteria for the diagnosis of multiple sclerosis to patients with clinically isolated syndromes. Eur J Neurol 20, 1510–1516.
17. ↵
    1. Saida T,
    2. Kikuchi S,
    3. Itoyama Y,
    4. Hao Q,
    5. Kurosawa T,
    6. Nagato K,
    7. et al.

    (2012) A randomized, controlled trial of fingolimod (FTY720) in Japanese patients with multiple sclerosis. Mult Scler 18, 1269–1277.
18. 1. Izquierdo G,
    2. O'Connor P,
    3. Montalban X,
    4. von Rosenstiel P,
    5. Cremer M,
    6. de Vera A,
    7. et al.

    (2014) Five-year results from a phase 2 study of oral fingolimod in relapsing multiple sclerosis. Mult Scler 20, 877–881.
19. ↵
    1. Calabresi PA,
    2. Radue EW,
    3. Goodin D,
    4. Jeffery D,
    5. Rammohan KW,
    6. Reder AT,
    7. et al.

    (2014) Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomized, placebo-controlled, phase 3 trial. Lancet Neurol 13, 545–556.
20. ↵
    1. Derfuss T,
    2. Bergvall NK,
    3. Sfikas N,
    4. Tomic DL

    (2015) Efficacy of fingolimod in patients with highly active relapsing-remitting multiple sclerosis. Curr Med Res Opin 31, 1687–1691.
21. ↵
    1. Lattanzi S,
    2. Danni M,
    3. Cerqua R,
    4. Taffi R,
    5. Provinciali L,
    6. Silvestrini M

    (2015) Prediction of disability progression in fingolimod-treated patients. J Neurol Sci 358, 432–434.
22. ↵
    1. Alroughani R

    (2014) Fingolimod-associated amenorrhea: a report of three cases. Multiple Sclerosis Journal 20, 1662–1664.
23. ↵
    1. Gold R,
    2. Comi G,
    3. Palace J,
    4. Siever A,
    5. Gottschalk R,
    6. Bijarnia M,
    7. et al.

    (2014) Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study. J Neurol 261, 267–276.
24. ↵
    1. Laroni A,
    2. Brogi D,
    3. Morra VB,
    4. Guidi L,
    5. Pozzilli C,
    6. Comi G,
    7. et al.

    (2014) Safety of the first dose of fingolimod for multiple sclerosis: Results of an open-label clinical trial. BMC Neurol 14, 65.
25. ↵
    1. Lattanzi S,
    2. Danni M,
    3. Taffi R,
    4. Cerqua R,
    5. Carlini G,
    6. Pulcini A,
    7. et al.

    (2017) persistence to oral disease modifying therapies in multiple sclerosis patients. J Neurol 264, 2325–2329.